Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Healthcare
/
Centene
CNC
Centene
Centene will surge to a $60 valuation within a year amidst market shifts
TM
TMav42
Not Invested
Community Contributor
Published
31 Jul 25
Updated
31 Jul 25
1
Set Fair Value
0
votes
Share
TMav42
's Fair Value
US$41.01
37.6% undervalued
intrinsic discount
31 Jul
US$25.59
Loading
1Y
-66.2%
7D
-2.4%
Author's Valuation
US$41.0
37.6% undervalued
intrinsic discount
TMav42's Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
TMav42
's
Fair Value
US$41.0
37.6% undervalued
intrinsic discount
Future estimation in
5 Years
time period
Past
Future
0
257b
2014
2017
2020
2023
2025
2026
2029
2030
Revenue US$257.0b
Earnings US$3.3b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
4.37%
Healthcare Services revenue growth rate
0.29%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.77%
Calculation
US$3.31b
Earnings '30
x
6.17x
PE Ratio '30
=
US$20.40b
Market Cap '30
US$20.40b
Market Cap '30
/
348.45m
No. shares '30
=
US$58.54
Share Price '30
US$58.54
Share Price '30
Discounted to 2025 @ 7.38% p.a.
=
US$41.01
Fair Value '25
